These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

913 related articles for article (PubMed ID: 33952621)

  • 1. Managing drug shortages during a pandemic: tocilizumab and COVID-19.
    Verma AA; Pai M; Saha S; Bean S; Fralick M; Gibson JL; Greenberg RA; Kwan JL; Lapointe-Shaw L; Tang T; Morris AM; Razak F
    CMAJ; 2021 May; 193(21):E771-E776. PubMed ID: 33952621
    [No Abstract]   [Full Text] [Related]  

  • 2. Practical Considerations for Converting Operating Rooms and Post-anaesthesia Care Units into Intensive Care Units in the COVID-19 Pandemic - Experience from a Large Singapore Tertiary Hospital.
    Tan Z; Phoon PHY; Tien CJ; Katijo J; Ng SY; Goh MH
    Ann Acad Med Singap; 2020 Dec; 49(12):1009-1012. PubMed ID: 33463659
    [TBL] [Abstract][Full Text] [Related]  

  • 3. COVID-19 in kidney transplant recipients: A multicenter experience in Istanbul.
    Demir E; Uyar M; Parmaksiz E; Sinangil A; Yelken B; Dirim AB; Merhametsiz O; Yadigar S; Atan Ucar Z; Ucar AR; Demir ME; Mese M; Akin EB; Garayeva N; Safak S; Oto OA; Yazici H; Turkmen A
    Transpl Infect Dis; 2020 Oct; 22(5):e13371. PubMed ID: 32657540
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcome of COVID-19 patients with use of Tocilizumab: A single center experience.
    Zain Mushtaq M; Bin Zafar Mahmood S; Jamil B; Aziz A; Ali SA
    Int Immunopharmacol; 2020 Nov; 88():106926. PubMed ID: 32889236
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Delayed inflammation decrease is associated with mortality in Tocilizumab-treated critically ill SARS-CoV-2 patients: A retrospective matched-cohort analysis.
    Urbina T; Lavillegrand JR; Garnier M; Mekinian A; Pacanowski J; Mario N; Dumas G; Hariri G; Pilon A; Darrivère L; Fartoukh M; Guidet B; Maury E; Leblanc J; Chantran Y; Fain O; Lacombe K; Voiriot G; Ait-Oufella H
    Innate Immun; 2022 Jan; 28(1):3-10. PubMed ID: 35089113
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Successful recovery from severe COVID-19 pneumonia after kidney transplantation: The interplay between immunosuppression and novel therapy including tocilizumab.
    Lauterio A; Valsecchi M; Santambrogio S; De Carlis R; Merli M; Calini A; Centonze L; Buscemi V; Bottiroli M; Puoti M; Fumagalli R; De Carlis L
    Transpl Infect Dis; 2020 Oct; 22(5):e13334. PubMed ID: 32449235
    [TBL] [Abstract][Full Text] [Related]  

  • 7. No evidence of tocilizumab treatment efficacy for severe to critical SARS-CoV2 infected patients: Results from a retrospective controlled multicenter study.
    Burlacu R; London J; Fleury A; Sené T; Diallo A; Meyssonnier V; Zeller V; Galland J; Huscenot T; Rubenstein E; Trouiller P; Amathieu R; Kutter J; Blondeel D; Lejour G; Mouly S; Lidove O; Wladimir M; Sène D
    Medicine (Baltimore); 2021 May; 100(21):e26023. PubMed ID: 34032722
    [TBL] [Abstract][Full Text] [Related]  

  • 8. COVID-19 treatment combinations and associations with mortality in a large multi-site healthcare system.
    Coppock D; Baram M; Chang AM; Henwood P; Kubey A; Summer R; Zurlo J; Li M; Hess B
    PLoS One; 2021; 16(6):e0252591. PubMed ID: 34115801
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tocilizumab treatment for COVID-19 patients: a systematic review and meta-analysis.
    Wei Q; Lin H; Wei RG; Chen N; He F; Zou DH; Wei JR
    Infect Dis Poverty; 2021 May; 10(1):71. PubMed ID: 34001244
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The COVIRL002 Trial-Tocilizumab for management of severe, non-critical COVID-19 infection: A structured summary of a study protocol for a randomised controlled trial.
    Cotter A; Wallace D; McCarthy C; Feeney E; O'Neill L; Stack J; McCarthy G; Hussain R; Alvarez Barco E; Doran P; Mallon P
    Trials; 2020 Sep; 21(1):758. PubMed ID: 32883328
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Proposed Lottery System to Allocate Scarce COVID-19 Medications: Promoting Fairness and Generating Knowledge.
    White DB; Angus DC
    JAMA; 2020 Jul; 324(4):329-330. PubMed ID: 32579158
    [No Abstract]   [Full Text] [Related]  

  • 12. Learning From COVID-19: System Blindness to Primary Care.
    Newton WP; Baxley E; Magill M
    Ann Fam Med; 2021; 19(3):282-284. PubMed ID: 34180855
    [No Abstract]   [Full Text] [Related]  

  • 13. Experience in the management of severe COVID-19 patients in an intensive care unit.
    Sosa-García JO; Gutiérrez-Villaseñor AO; García-Briones A; Romero-González JP; Juárez-Hernández E; González-Chon O
    Cir Cir; 2020; 88(5):569-575. PubMed ID: 33064694
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Observational study on off-label use of tocilizumab in patients with severe COVID-19.
    Albertini L; Soletchnik M; Razurel A; Cohen J; Bidegain F; Fauvelle F; Safrano G; Piquet J; Maurer C; Goldgran-Toledano D
    Eur J Hosp Pharm; 2021 Jan; 28(1):22-27. PubMed ID: 32912961
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Promising effects of tocilizumab in COVID-19: A non-controlled, prospective clinical trial.
    Dastan F; Saffaei A; Haseli S; Marjani M; Moniri A; Abtahian Z; Abedini A; Kiani A; Seifi S; Jammati H; Hashemian SMR; Pourabdollah Toutkaboni M; Eslaminejad A; Heshmatnia J; Sadeghi M; Nadji SA; Dastan A; Baghaei P; Varahram M; Yousefian S; Salamzadeh J; Tabarsi P
    Int Immunopharmacol; 2020 Nov; 88():106869. PubMed ID: 32889241
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tocilizumab as a Therapeutic Agent for Critically Ill Patients Infected with SARS-CoV-2.
    Petrak RM; Skorodin NC; Van Hise NW; Fliegelman RM; Pinsky J; Didwania V; Anderson M; Diaz M; Shah K; Chundi VV; Hines DW; Harting BP; Sidwha K; Yu B; Brune P; Owaisi A; Beezhold D; Kent J; Vais D; Han A; Gowda N; Sahgal N; Silverman J; Stake J; Nepomuceno J; Heddurshetti R
    Clin Transl Sci; 2021 Nov; 14(6):2146-2151. PubMed ID: 32918792
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and Safety of Tocilizumab for Coronavirus Disease 2019 (Covid-19) Patients: A Systematic Review and Meta-analysis.
    Hariyanto TI; Hardyson W; Kurniawan A
    Drug Res (Stuttg); 2021 May; 71(5):265-274. PubMed ID: 33401328
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-IL-6 receptor antibody treatment for severe COVID-19 and the potential implication of IL-6 gene polymorphisms in novel coronavirus pneumonia.
    Ulhaq ZS; Soraya GV
    Med Clin (Barc); 2020 Dec; 155(12):548-556. PubMed ID: 32950258
    [No Abstract]   [Full Text] [Related]  

  • 19. SARS-CoV-2 infection in kidney transplant recipients: Experience of the italian marche region.
    Maritati F; Cerutti E; Zuccatosta L; Fiorentini A; Finale C; Ficosecco M; Cristiano F; Capestro A; Balestra E; Taruscia D; Vivarelli M; Donati A; Perna GP; Giacometti A; Tavio M; Onesta M; Di Sante L; Ranghino A
    Transpl Infect Dis; 2020 Oct; 22(5):e13377. PubMed ID: 32573895
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Severe COVID-19 Infections-Knowledge Gained and Remaining Questions.
    Bos LDJ; Brodie D; Calfee CS
    JAMA Intern Med; 2021 Jan; 181(1):9-11. PubMed ID: 32945833
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 46.